Session 4: Cancer Flashcards

1
Q

What are the first 6 hallmarks of cancer and cancer and their therapeutic targets?

A
  1. Sustaining proliferative signalling.
    - EGFR inhibitors
  2. Evading growth suppressors
    - cyclin-dependent kinase inhibitors
  3. Activation invasion and metastasis
    - HGF/c-MET inhibitors
  4. Enabling replicative immortality
    - telomerase inhibitors
  5. inducing angiogenesis
    -inhibitors of VEGF signalling
  6. Resisting cell death
    - proapoptotic BH3 mimetics
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How do cells sustain proliferative signalling?

A

Normal physiology: cells respond to growth factors which bind to GF receptors.
This phosphorylates and activates Ras which phosphorylates and activates transcription factors in a signalling cascase, leading to cell division.

Two mechanisms:

  1. in some cancers, Ras mutation means no ligand is required for activation. Ras phosphorylates downstream signalling proteins regardless of ligan presence.
  2. Some cancers have amplified GF receptors and there are more signals produced, cell division and survival is increased, promoting malignant expansion of the cell.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How do tumour cells evade suppressors?

A

Normal physiology: DNA damage triggers p53 activation for DNA repair. If repair fails, cells may undergo arrest and apoptosis or become senescent.

Cancer can suppress p53, leading to mutation accumulation and tumour growth.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What are the additional hallmarks of cancer?

A

What are the additional hallmarks of cancer?
7. Avoid immune destruction - immune activating anti-CTLA4 mAb
8. Tumour-promoting inflammation - selective anti-inflammatory drugs
9. Genome instability - PARP inhibitors
10. Deregulating cellular energetics - aerobic glycolysis inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Give examples of how cancer cells can resist cell death

A

Cancerous cells can avoid apoptosis by:
-Downregulation of: MAPK activity, NF-kappaB, caspases 3, 8, 9, p53.
-Upregulation of Bcl-2, Bc-XL, TNFAIP8

These mechanisms increase cell cycle and drug resistance.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

How do cancer cells exhibit replicative immortality?

A

Telomeres = chromosome ends
Normal physiology = telomeres are made by telomerase early in development, then telomerase activity is turned off. Telomeres shorten with each cell division, ultimately leading to senescence.
In some cancers, telomerase is constitutively active so more telomeres are added, leading to the survival of cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What is tumour angiogenesis?

A

Tumours secrete vascular endothelial growth factor, increasing blood vessel expression and movement to the tumour. Tumour has an increased blood supply, promoting survival.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How are invasion and metastasis activated?

A

Cancer development is a multistep process. Individual steps can occur in a different order.
E-cadherin promotion/ mutation leads to tissue invasion and metastasis.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What are the enabling characteristics of cancer?

A
  • genome instability and mutation
  • tumour promoting inflammation
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What classes of anti-cancer therapy are there? Give examples.

A
  • Classical chemotherapy: alkylation, anthracyclines, taxanes, anti-metabolites, nucleoside analogues, vinca alkaloids.
  • Corticosteroids
  • mAB: single specificity, bi-specific, toxin-conjugated, radio-label conjugated
  • immunomodulation: thalidomide, lenalidomide, pomalidomide
  • Angiogenesis inhibitors: bevacizumab
  • BCL2 inhibitors: venetoclax
  • Immunotherapy: checkpoint inhibitors
  • Chimeric antigen receptor T cells.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

What is the role of classical chemotherapy?

A

Target cellular proliferation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What class of drugs are vinca alkaloids and what is their role?

A

Classical chemotherapy, inhibit tubulars in mitotic processes.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the main side effects of classical chemotherapy?

A

Hair loss, mucosal SE e.g. diarrhoea and vomiting, bone marrow anaemia, low platelets = bleeding, recurrent infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the role of corticosteroids?

A

Directly kill some leukaemia, reduce inflammation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the role of mAb?

A

Target surface proteins on cancer cells. Can bring T cells to cancer cell to kill it. OR it can be tagged to a toxin or radioactive molecule for targeting.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

What type of cancers does thalidomide target?

A

Myeloma.

17
Q

What is the role of kinase inhibitors?

A

Inhibits element of signalling pathway to inhibit growth promotion.

18
Q

What is the role of Venetoclax?

A

Inhibits anti-apoptotic protein BCL-2.

19
Q

What is the role of chimeric antigen receptor T cells?

A

Engineering T cells to target cancer.

20
Q

What is Chronic Myeloid Leukaemia (CML)?

A

Cancer of the haematopoietic stem cell.
Philadelphia (Ph) chromosome (9,22 translocation).
Chronic phase typical duration around 4 years.
Blast crisis.
BCR-ABL kinase transforms haematopoietic progenitor into a malignant clone.

21
Q

What is an interferon?

A

Stimulates immune system B and T cells to kill or senesce cells.

22
Q

What are the side effects of interferons?

A

Significant toxicities related to multiple off-target effects.
SE= aches, headaches, depression.

23
Q

How is damage of interferons reduced?

A

Conjugates of interferon with polyethylene glycol (PEG) prolongs its half-life so less dose is required.

24
Q

What are the pros and cons of Ara-C?

A

Effective in lymphoid cancers

Non-specific, off-site target effects especially bone marrow.

25
Q

What is the MoA of ‘Ara-C’ aka cytarabine?

A

A nucleoside analogue.
1. drug is internalised by nucleoside transporter 2. Conversion to cytarabine-5’-triphosphate
3. Fake nucleotide incorporation in DNA.
Induces apoptosis, inhibits DNA transcription and duplication.

26
Q

What is the MoA of Imatinib?

A
  • inhibits abnormal BCR-ABL tyrosine kinase found in some cancers
  • blocks binding of ATP to tyrosine kinase, prevents phosphorylation of the substrate
  • Signalling protein is not turned on, transcription factors are not upregulated and cells do not proliferate.

Imatinib is only effective in CML

27
Q

What are the benefits of imatinib?

A
  • Targeted therapy
  • More effective than previous chemotherapy
  • Fewer side effects
  • less toxic
  • More acceptable oral medicine
  • some patients functionally cured